- Home
- ASTC vs BGMS Comparison
ASTC vs BGMS Comparison
Compare ASTC & BGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASTC | BGMS |
|---|---|---|
| Founded | 1984 | 1996 |
| Country | United States | Malaysia |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASTC | BGMS |
|---|---|---|
| Price | $2.77 | $0.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.5K | ★ 146.6K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | N/A |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | $137.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.47 | $0.74 |
| 52 Week High | $8.01 | $6.70 |
Technical Indicators
Market Signals| Indicator | ASTC | BGMS |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.77 |
| Support Level | N/A | $0.74 |
| Resistance Level | N/A | $1.66 |
| Average True Range (ATR) | 0.00 | 0.12 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 43.71 |
Price Performance
Historical ComparisonAbout ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About BGMS Bio Green Med Solution Inc.
Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.